—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Novo Nordisk A/S (NOVO-B.CO) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for NOVO-B.CO, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06

Company snapshot — Novo Nordisk A/S

NOVO-B.CO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Novo Nordisk researches, manufactures and distributes pharmaceutical products through two segments, one for obesity and diabetes care and cardiovascular disease, the other for rare blood disorders, rare endocrine conditions and hormone replacement therapy. Its product range includes smart insulin pens, dose-guidance software, growth-hormone injectors and needles, and Wegovy, an oral GLP-1 receptor agonist used for weight management. It sells across Europe, North America, Asia, Latin America, the Middle East and Africa, and is headquartered in Bagsvaerd, Denmark, having been founded in 1923.
Where it sits in the stack
Novo Nordisk holds no seat in our AI-focused index; it sits in the diary's wider universe under Healthcare, in the drug-manufacturing sleeve that tracks large pharmaceutical firms outside the compute build-out.
Who it is priced against
The diary has no peer group listed for it; the obvious market comparison is Eli Lilly, its closest rival in GLP-1-based obesity and diabetes treatments.
Why Closelooknet tracks it
It carries no Closelooknet index seat and no score yet, and the diary has not quoted it in any edition so far, so coverage here stays limited to what can be confirmed.
What the diary watches
The diary watches whether the recent slide below its 50-day and 200-day averages, and its pull-back from the 52-week high, signals a shift in sentiment toward its obesity franchise.

Novo Nordisk A/S (NOVO-B.CO) trades on the CO exchange in Denmark.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 4.77%, semi-annual · last 3.77 DKK on 2026-08-13

Dividends and capital return

What NOVO-B.CO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 11.72 DKK per share · a 4.77% yield on the 2026-10-06 close 2 distributions, paid twice a year 2026-10-06
  • Change on the year +0.6% against the prior twelve months prior twelve months 11.65 DKK per share
  • Last distribution 3.77 DKK per share as the price series records it, within days of the ex-date 2026-08-13
  • By calendar year 2024: 3.50 DKK (partial) · 2025: 11.65 DKK · 2026: 11.72 DKK to date first distribution recorded in the three-year window: 2024-08-15

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Novo Nordisk A/S (NOVO-B.CO)?

Novo Nordisk A/S trades as NOVO-B.CO on the CO exchange (Denmark) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is NOVO-B.CO in a Closelooknet index?

Not currently — Novo Nordisk A/S is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does NOVO-B.CO trade against its moving averages?

Downtrend stack: Trades -14.1% vs the 50-day and -15.6% vs the 200-day average, 38% below the 52-week high and +13.3% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does Novo Nordisk A/S do?

Novo Nordisk researches, manufactures and distributes pharmaceutical products through two segments, one for obesity and diabetes care and cardiovascular disease, the other for rare blood disorders, rare endocrine conditions and hormone replacement therapy. Its product range includes smart insulin pens, dose-guidance software, growth-hormone injectors and needles, and Wegovy, an oral GLP-1 receptor agonist used for weight management. It sells across Europe, North America, Asia, Latin America, the Middle East and Africa, and is headquartered in Bagsvaerd, Denmark, having been founded in 1923. The diary has no peer group listed for it; the obvious market comparison is Eli Lilly, its closest rival in GLP-1-based obesity and diabetes treatments.

Where does Novo Nordisk A/S sit in the AI build-out?

Novo Nordisk holds no seat in our AI-focused index; it sits in the diary's wider universe under Healthcare, in the drug-manufacturing sleeve that tracks large pharmaceutical firms outside the compute build-out. It carries no Closelooknet index seat and no score yet, and the diary has not quoted it in any edition so far, so coverage here stays limited to what can be confirmed.

Does Novo Nordisk A/S pay a dividend?

Novo Nordisk A/S has paid 11.72 DKK per share over the last twelve months, paid twice a year, a trailing yield of 4.77% on the 2026-10-06 close; the last distribution recorded in the price series was 3.77 DKK on 2026-08-13. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for NOVO-B.CO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.